Zhang et al. reported that the deletions of CDKN2A/B were associated with unfavorable prognosis in both adult and pediatric patients with ALL thereby suggesting that the assessment of CDKN2A/B status could potentially enhance risk stratification of ALL patients. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.